Dow Jones 30 Stocks SEC Filings — May 06, 2026

06-05-2026

PARKE BANCORP, INC. reported robust Q1 2026 financial results with net income of $11,844 thousand (up 52% YoY from $7,778 thousand), driven by net interest income growth of 33% to $22,132 thousand and a reduced provision for credit losses to $202 thousand from $590 thousand. However, total assets contracted 2% QoQ to $2,212,935 thousand, reflecting a 29% decline in cash and cash equivalents to $110,874 thousand and a 3% drop in total deposits to $1,698,744 thousand, while noninterest-bearing deposits fell 16% QoQ. Shareholders' equity increased 3% QoQ to $335,563 thousand supported by earnings retention despite common stock dividends of $2,119 thousand.

• ·Basic EPS $1.01 vs $0.66 YoY; Diluted EPS $0.99 vs $0.65 YoY
• ·Common stock dividend $0.18 per share ($2,119 thousand total); Preferred dividend $15.00 per share ($5 thousand total)
• ·Gross loans increased 0.4% QoQ to $2,043,296 thousand
• ·Non-interest expense increased 10% YoY to $7,214 thousand, with compensation up 13% to $3,704 thousand
• ·Cash flow from operating activities $13,019 thousand vs $6,999 thousand YoY
• ·Net cash used in financing activities $50,799 thousand, driven by deposit outflows

06-05-2026

Viper Energy, Inc. reported robust Q1 2026 quarterly results with total operating income surging 108.6% YoY to $511 million, driven by royalty income of $496 million (up 103.3% YoY) including oil income of $428 million (up 112.9% YoY), and net income attributable to Viper rising 29.3% YoY to $97 million. However, basic EPS declined 12.9% YoY to $0.54 amid a 50.0% increase in weighted average basic shares to 181,304 thousand, depletion expenses more than tripled to $206 million, and total assets dipped slightly QoQ to $12,048 million. Operating cash flow strengthened 63.2% YoY to $328 million, supported by $581 million net cash from investing activities including $611 million proceeds from property sales, while long-term debt was reduced 26.6% QoQ to $1,603 million.

• ·Repurchases of $50 million Class A common stock and $46 million OpCo Units under repurchase program in Q1 2026.
• ·Dividends to stockholders of $100 million and to Diamondback of $93 million in Q1 2026.
• ·Royalty income from Diamondback operated properties: $245 million (up 68.97% YoY); third-party operated: $251 million (up 153.54% YoY).
• ·Acquisitions of oil and natural gas properties: $18 million (unrelated party) and $12 million (related party) in Q1 2026.

06-05-2026

Ingevity reported first quarter 2026 net sales of $258.0 million, up 4% YoY driven by 6% growth in Performance Materials, though Performance Chemicals sales were flat at $58.3 million with Road Markings down 10% and segment EBITDA plunging to $0.6 million from $5.8 million. Adjusted EBITDA remained flat at $91.5 million but with margin contracting to 35.5% from 36.8%, while net income from continuing operations declined to $23.4 million from $29.1 million due to $22.7 million in pre-tax special charges. The company completed divestitures of Industrial Specialties for ~$93 million and Road Markings for ~$65 million in net proceeds, repurchased $52 million in shares, and reaffirmed full-year guidance.

• ·Operating cash flow Q1 2026: negative $2.0 million vs positive $25.4 million prior year.
• ·Full year 2026 guidance: net sales $1.05-$1.15 billion; adjusted EBITDA $370-$395 million; adjusted EPS $4.70-$5.20; free cash flow $215-$245 million (excl. $113.2M BASF settlement).
• ·Remaining share repurchase authorization capacity: $246 million.
• ·Q1 2026 adjusted EBITDA margin: 35.5% (down 130 bps YoY).
• ·Performance Materials EBITDA margin: 59.2% (up 230 bps YoY).

06-05-2026

At the 2026 Annual General Meeting on May 5, 2026, RenaissanceRe Holdings Ltd. shareholders elected four Class I directors—James L. Gibbons, Shyam Gidumal, Stephen C. Hooley, and Torsten Jeworrek—to serve until 2029, approved an advisory vote on named executive officer compensation, ratified the appointment of PricewaterhouseCoopers Ltd. as independent auditor, and approved the 2026 Long-Term Incentive Plan authorizing 1,250,000 common shares plus shares remaining from the prior plan. All proposals passed with a quorum of 40,162,748 shares (93.06% of 43,153,808 outstanding shares), though the LTIP faced notable opposition with 9,490,927 votes against compared to 28,846,544 for.

• ·Director election votes: James L. Gibbons (For: 34,398,054; Against: 4,005,559); Shyam Gidumal (For: 36,300,904; Against: 2,102,244); Stephen C. Hooley (For: 37,067,648; Against: 1,335,998); Torsten Jeworrek (For: 36,662,152; Against: 1,741,496).
• ·Exec comp advisory: For 37,045,795; Against 1,353,449.
• ·Auditor ratification: For 40,132,329; Against 2,946.

06-05-2026

OSR Holdings, Inc. and its subsidiary Vaximm AG entered into a definitive Global Exclusive License Agreement dated April 29, 2026, granting BCM Europe AG exclusive worldwide rights to VXM01 for up to $815 million in clinical, regulatory, and commercial milestones, plus full royalty pass-through after delta recovery. The transaction includes a $30 million intercompany development financing facility (excluded from fairness analysis) and an OSRH option to issue $15 million in common stock at a $10.00 per share premium to market. An independent fairness opinion from Avance, Basel GmbH dated April 21, 2026, deems the financial terms fair to Vaximm, OSRH, and unaffiliated shareholders, though it excludes the blockchain-based royalty mechanism due to insufficient details.

• ·License term continues until expiration of all VXM01-related patents worldwide or final commercial royalty payment from ultimate licensee.
• ·Transaction is a related-party deal as BCM Europe AG is OSRH's largest shareholder.
• ·Fairness opinion scope excludes blockchain TAC token mechanism, development financing facility, scientific/regulatory merits, and tax/accounting matters.

06-05-2026

Futurewave Acquisition Corp, a Cayman Islands blank check company formed on February 16, 2026, has filed an S-1 registration statement for an IPO of 5,000,000 units (or 5,750,000 if over-allotment exercised) at $10.00 per unit, targeting gross proceeds of $50,000,000, with $10.00 per unit deposited into a U.S. trust account for an initial business combination. Net proceeds before expenses are $49,625,000 after $375,000 in underwriting discounts. However, public shareholders face substantial dilution, with pro forma net tangible book value per share dropping to as low as $0.29 (maximum redemptions) from an adjusted offering price of $8.00, resulting in dilution up to $7.73 per share.

• ·Company qualifies as emerging growth company with reduced reporting requirements.
• ·Units expected to list on Nasdaq as FWAC, FWACW, FWACR.
• ·Founder shares subject to up to 321,750 forfeiture if over-allotment not exercised.
• ·Pro forma net tangible book value per share without over-allotment: $5.09 (25% redemptions), $4.12 (50%), $2.68 (75%), $0.29 (100%).
• ·Dilution to public shareholders without over-allotment: $2.91 (25% redemptions), $3.88 (50%), $5.32 (75%), $7.71 (100%).
• ·Financial data as of March 31, 2026.

06-05-2026

NewAmsterdam Pharma Company N.V. has issued a proxy statement for its Annual General Meeting on June 2, 2026, seeking shareholder approval for adoption of the Dutch statutory annual accounts for FY ended December 31, 2025, discharge of director liability, reappointment of Deloitte Accountants B.V. as auditor, reappointment of non-executive directors John W. Smither and Janneke van der Kamp, extensions of share issuance authorizations, approval of the 2026 Employee Stock Purchase Plan, and a non-binding advisory vote on 2025 named executive officer compensation. The record date is May 5, 2026, with attendance notices and proxies due by 11:59 p.m. ET on May 31, 2026. No specific financial performance metrics or period-over-period comparisons are disclosed in the provided filing content.

• ·Annual General Meeting location: offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, Netherlands at 5:00 p.m. CEST on June 2, 2026.
• ·Dutch statutory board report and annual accounts for FY 2025 available no later than May 18, 2026 on company website.
• ·Proxy submission options: toll-free telephone (1-800-690-6903), www.proxyvote.com, or mail.

06-05-2026

UWM Holdings Corporation reported Q1 2026 loan origination volume of $44.9 billion, up 39% YoY from $32.4 billion and the second-highest Q1 in company history, with total revenue of $901.4 million (up 47% YoY) and net income of $170.4 million versus a $247.0 million loss in Q1 2025. However, QoQ performance showed declines, including origination volume down 9% from $49.6 billion, revenue down 5% from $945.2 million, purchase originations down 14% YoY and nearly flat QoQ, and adjusted EBITDA down 31% from $232.8 million. Gain margin improved to 123 bps from 94 bps YoY but was slightly up from 122 bps QoQ.

• ·Subsequent to Q1 2026, Board declared $0.10 per share cash dividend on Class A common stock, payable July 9, 2026 to shareholders of record June 18, 2026.
• ·All new loans now on UWM’s proprietary servicing platform, on pace for substantially all loans serviced in-house by October 2026.
• ·Non-funding debt to equity ratio increased to 3.18 at Q1 2026 end from 1.93 in Q1 2025.
• ·Cash and cash equivalents $424.0 million at March 31, 2026.

06-05-2026

Two Harbors Investment Corp. (TWO) filed a DEFA14A proxy statement urging shareholders to vote FOR the all-cash acquisition by CCM at $11.30 per share, a 14% premium to the unaffected share price of $9.91 as of Dec 16, 2025 and 12% to diluted tangible book value per share of $10.12 as of March 31, 2026. The Board highlights fully committed financing, integration planning, and a clear path to close in Q3 2026 with HSR waiting period expiring May 26, 2026, while deeming UWMC's revised stock-based proposal inferior due to financing risks, uncertain value, and longer timeline. A special stockholder meeting is scheduled for May 19, 2026.

• ·Board and Ad Hoc Committee met 30 times from Dec 2024 to May 2026 evaluating proposals from UWMC (10+), CCM (7+), Company A (5), Company B (2).
• ·CCM improved offer from $10.70 to $11.30 per share; supported by Houlihan Lokey fairness opinion.
• ·Over 20 state mortgage licensing approvals obtained; all required filings submitted.
• ·UWMC revised proposals rejected as inferior, including $11.30/share cash election and later $12.00/share cash election with default stock at 2.3328 exchange ratio.

06-05-2026

Solstice Advanced Materials reported first quarter 2026 net sales of $991 million, up 10% YoY, with strong growth in Nuclear (+27%), Refrigerants (+19%), Electronic Materials (+21%), and Healthcare Packaging (+9%). However, net income attributable to the company declined 37% to $85 million, diluted EPS fell to $0.53, adjusted EBITDA was flat at $249 million with margin down 277 bps to 25.1%, RAS segment EBITDA decreased 3% with Building Solutions & Intermediates down 8%, and corporate expenses rose to $52 million. The company reaffirmed full-year 2026 guidance for net sales of $3.9-4.1 billion and adjusted EBITDA of $975-1,025 million.

• ·Quarterly cash dividend of $0.075 per share approved, payable June 10, 2026 to shareholders of record May 27, 2026.
• ·Net Leverage ratio of approximately 1.4x based on trailing twelve-month Adjusted EBITDA.
• ·Q2 2026 guidance: Net Sales $1.06-1.1 billion; Adjusted EBITDA Margin 25-26%.
• ·FY2026 guidance: Adjusted diluted EPS $2.45-$2.75; Capital Expenditures $400-425 million.
• ·Corporate Expenses $52 million in Q1 2026 vs $32 million in Q1 2025.
• ·Nuclear Business webinar scheduled for June 4, 2026.

06-05-2026

Acushnet Holdings Corp. reported first quarter 2026 net sales of $753.0 million, up 7.1% year over year (4.8% in constant currency), driven by an 8.9% increase in Titleist golf equipment and 10.8% growth in Golf gear. However, net income attributable to the company declined 18.1% to $81.4 million, primarily due to a prior-year non-cash pre-tax gain of $20.9 million from the FootJoy JV deconsolidation, while Adjusted EBITDA rose 4.1% to $144.6 million; FootJoy golf wear grew modestly 1.7% but declined 1.3% on a constant currency basis.

• ·Board declared quarterly cash dividend of $0.255 per share, payable June 22, 2026 to shareholders of record June 5, 2026.
• ·Repurchased 106,008 shares at average price $94.12 for $10.0 million during Q1 2026.
• ·Reaffirmed FY2026 outlook: consolidated net sales $2,625-$2,675 million (2.5%-4.5% constant currency growth), Adjusted EBITDA $415-$435 million.
• ·Adjusted EBITDA margin 19.2% vs. 19.7% prior year.
• ·Investor conference call held May 6, 2026 at 8:30 a.m. ET.

06-05-2026

LivaNova PLC reported Q1 2026 revenue of $362.3 million, up 14.3% reported and 11.1% constant-currency YoY, driven by 18.3% reported growth in Cardiopulmonary to $208.7 million and 9.3% in Neuromodulation to $151.8 million; however, Other Revenue was flat at -0.2% constant-currency despite 10.5% reported growth to $1.8 million, and GAAP operating income declined to $41.5 million from $48.6 million. Adjusted diluted EPS rose to $0.98 from $0.88, prompting raised FY2026 guidance to 7.0-8.0% constant-currency revenue growth and $4.20-$4.30 adjusted EPS. The company also received FDA PMA for the aura6000 System for OSA treatment.

• ·FY2026 adjusted diluted EPS guidance raised to $4.20-$4.30 (midpoint +$0.05) from $4.15-$4.25, assuming ~56 million shares.
• ·FY2026 adjusted free cash flow guidance maintained at $160M-$180M.
• ·Q1 2026 GAAP diluted EPS of $0.40 vs. Q1 2025 loss of $6.01 (impacted by $360.4M SNIA expense).

06-05-2026

VITASPRING BIOMEDICAL CO. LTD. reported zero revenues for both the three months ended October 31, 2024 and 2023, and for the nine months ended October 31, 2024 versus 2023, with net losses improving to $196,292 (from $234,980) and $631,785 (from $893,164) respectively due to lower SG&A expenses. However, total assets declined sharply 57.5% to $58,382 from $137,342 as of January 31, 2024, driven by reductions in long-term assets, while liabilities rose 12.7% to $3,930,445, widening the stockholders' deficit to $3,872,063. Cash increased modestly to $2,062 from $13, supported by reduced operating cash burn of $12,885 versus $32,297 for the nine months.

• ·Equipment and vehicle, net declined to $16,595 from $24,063 as of January 31, 2024.
• ·Accounts payable - related party steady at $2,411,000.
• ·Stock-based compensation totaled $109,911 for nine months ended October 31, 2024.
• ·Operating lease right-of-use asset fully impaired to $0 from $89,652.

06-05-2026

Barrel Energy Inc. dismissed Fruci & Associates II, PLLC as its independent registered public accounting firm on April 28, 2026, following their audits of fiscal years 2023 and 2024 and review of financials through September 30, 2025. The Company engaged Shah Teelani & Associates Chartered Accountants on April 21, 2026, to audit the fiscal year ended December 31, 2025. No disagreements on accounting principles, financial disclosures, auditing scope, or reportable events occurred with the prior auditor.

• ·Previous auditor provided services for Form 10 filed February 23, 2026.
• ·Letter from Fruci & Associates II, PLLC to be filed by amendment as Exhibit 16.1.
• ·Company address: 3859 S Valley View Blvd, Ste 2 #107, Las Vegas, NV 89103.

06-05-2026

TCFG Investment Advisors, LLC filed a 13F-HR report disclosing its holdings as of March 31, 2026, with a total portfolio value of $267470940 across 274 positions, all held with sole voting power. Top holdings include Apple Inc. COM at $14964597 (58964 shares), NVIDIA Corporation COM at $13224244 (75827 shares), and Amazon.com Inc COM at $5801806 (27857 shares). No changes or performance metrics were detailed in the filing.

• ·Filing date: May 06, 2026
• ·Report period end: March 31, 2026
• ·All 274 positions held as SH SOLE with no other voting or disposition power indicated

06-05-2026

On May 5, 2026, Patriot National Bancorp, Inc. posted a presentation on its Investor Relations website containing certain Q1 2026 financial information for its wholly owned subsidiary, Patriot Bank, National Association. The presentation is furnished as Exhibit 99.1 under Items 7.01 and 9.01 of this Form 8-K. This disclosure is made pursuant to Regulation FD and is not deemed 'filed' for purposes of the Exchange Act.

• ·Investor Relations website: https://bankpatriot.com/Learn/About/Investor-Relations
• ·Filing pertains to Q1 2026 financial information

06-05-2026

Shengqi Capital (Hong Kong) Ltd filed its quarterly 13F-HR on May 6, 2026, disclosing equity holdings as of March 31, 2026, with a total portfolio value of approximately $40.9 million. The largest position is 100 shares of Alphabet Inc Class C stock valued at $28.686 million, followed by 200 shares of ProShares UltraPro QQQ valued at $8.336 million, 100 shares of iShares Bitcoin Trust ETF valued at $3.842 million, and 100 shares of Greenland Mines Ltd valued at $0.033 million. No prior period comparisons are provided in the filing.

• ·Filing signed by Lau Ka Chun on April 14, 2026
• ·All holdings reported as sole voting power with no shared voting, puts/calls, or other managers
• ·Company address: Room 1805, 90 Connaught Rd Central, Sheung Wan, Hong Kong

06-05-2026

Skyworks Solutions, Inc. updated on its proposed merger with Qorvo, Inc. during its Q2 FY2026 earnings call on May 5, 2026, stating regulatory reviews are progressing as expected with entry into Phase II of the China SAMR review and increasing hope for a late 2026 close ahead of formal early 2027 guidance. The company expressed strong confidence in achieving at least $500 million in anticipated synergies and supported Qorvo's $400 million share repurchase per merger agreement covenants. No delays or setbacks were highlighted, with integration planning advancing well.

• ·Entered Phase II of China SAMR regulatory review
• ·Registration Statement on Form S-4 (File No. 333-291947) declared effective December 23, 2025
• ·Formal merger closing guidance: early calendar 2027

06-05-2026

Life Time Group Holdings, Inc. agreed to repurchase 2,192,500 shares of its common stock at $28.60 per share for an aggregate $62,705,500 from existing stockholders, including affiliates of Leonard Green & Partners, L.P., TPG Inc., and Partners Group (USA) Inc. These selling stockholders are concurrently selling 8,770,000 shares at the same price for $250,822,000 to an affiliate of Atairos Group, Inc., for a total of 10,962,500 shares sold. Following the transactions, the selling funds will hold approximately 8.5%, 6.1%, and 1.3% of the Company's common stock based on 222,602,738 shares outstanding as of May 1, 2026.

• ·Investor Purchase expected to settle in two tranches, with second tranche after HSR Act waiting period expires or terminates.
• ·Share Repurchase funded with cash on hand.
• ·Selling Stockholders include affiliates of Leonard Green & Partners, L.P., TPG Inc., and Partners Group (USA) Inc.

06-05-2026

Clear Channel Outdoor Holdings reported first quarter 2026 consolidated revenue of $373,864 thousand, up 11.9% YoY from $334,180 thousand, with strong growth in America (+9.6% to $278,487 thousand) and Airports (+19.1% to $95,226 thousand), and Adjusted EBITDA rising 31.0% to $103,847 thousand. However, loss from continuing operations was $49,447 thousand (improved 10.6% from $55,302 thousand), consolidated net loss was $47,994 thousand versus prior-year net income of $63,213 thousand, and corporate expenses increased 55.8% to $30,818 thousand. The company provided an update on its pending take-private merger by affiliates of Mubadala Capital and TWG Global at $2.43 per share, expected to close by end of Q3 2026, with no earnings call or guidance due to the merger.

• ·Special meeting of stockholders scheduled for May 12, 2026 to vote on Merger Agreement.
• ·Hart-Scott-Rodino waiting period expired April 9, 2026.
• ·Cash and cash equivalents $195.5 million as of March 31, 2026 (including discontinued operations).
• ·Net debt $4,922,869 thousand as of March 31, 2026.
• ·Expected cash interest: $308 million for remainder of 2026, $391 million in 2027.
• ·Next significant debt maturities in 2028: $899.3 million 7.750% Senior Notes and $425.0 million Term Loan Facility.
• ·Operates in 81 U.S. DMAs, including 43 of top 50.

06-05-2026

VISTA CAPITAL PARTNERS, INC. filed its 13F-HR on May 06, 2026, disclosing holdings in 156 securities totaling $994149469 as of March 31, 2026. The portfolio features heavy ETF allocations, led by Vanguard Total U.S. Stock Market Index Fund at $358654303, Vanguard Value Index Fund at $149722873, and Vanguard REIT Index Fund at $128473633. Notable individual stock positions include Microsoft Corp ($12023179), Apple Inc ($12845347), and Nvidia Corp ($6043165), with no comparative prior period data provided.

• ·All positions reported with sole voting power
• ·Adviser CIK: 0001486946
• ·SEC file number: 028-14437
• ·Adviser ID: 801-60536

06-05-2026

VSM Wealth Advisory, LLC filed its 13F-HR on May 6, 2026, reporting 505 equity positions with a total market value of $334,834,908 as of March 31, 2026, all held with sole voting power. Notable holdings include Dimensional US Core Market ETF ($10,022,624), Dimensional U.S. Market ETF ($8,747,556), and Dimensional U.S. Core Equity 2 ETF ($8,543,092), alongside individual stocks like Apple Inc. ($2,826,656). The portfolio shows no reported changes in ownership structure or performance metrics.

• ·Filing period end date: March 31, 2026
• ·Date as of change: May 5, 2026
• ·All positions reported as SH SOLE (sole voting power), with no shared power, none or other

06-05-2026

Anthracite Investment Company, Inc. filed a 13F-HR institutional holdings report for the period ending March 31, 2026, on May 6, 2026. The filing reports no holdings, with all values indicated as 0 (e.g., 000000000 shares sole). It was signed by William B. Holloway, Jr., Chief Operating Officer.

• ·CIK: 0001809930
• ·SEC File Number: 028-23657
• ·State of Incorporation: TX
• ·Fiscal Year End: 12/31
• ·Business Address: 640 Taylor Street, Suite 2400, Fort Worth, TX 76102

06-05-2026

Bread Financial Holdings, Inc. announced the pricing of an underwritten public offering of 4,800,000 depositary shares, each representing a 1/40th interest in a share of its 8.875% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B, with a liquidation preference of $25 per depositary share. The underwriters, led by Morgan Stanley & Co., LLC and others, were granted an option to purchase up to an additional 720,000 depositary shares within 30 days. Net proceeds will be used for general corporate purposes, potentially including contributions to subsidiary Comenity Capital Bank and share repurchases.

• ·Offering registered under Securities Act on Form S-3 (Registration No. 333-291573).
• ·Prospectus supplement dated May 5, 2026, to be filed pursuant to Rule 424(b).
• ·Underwriting agreement dated May 5, 2026.

06-05-2026

Kingstone Capital Partners Texas, LLC disclosed 57 equity positions totaling $162415000 as of March 31, 2026, in its 13F-HR filing submitted on May 6, 2026. Top holdings include NVIDIA Corporation at $24019000, Alphabet Inc. Cap Stk Cl C at $10212000, and Apple Inc. at $7658000, with all positions held under sole investment discretion and voting authority. The portfolio features a mix of large-cap tech stocks, ETFs, and income-focused securities.

• ·All 57 positions held with SH SOLE investment discretion and sole voting authority.
• ·Portfolio includes significant allocations to tech (NVIDIA, Alphabet, Apple), mortgage REITs (AGNC, Annaly, Dynex), and income ETFs (Eaton Vance funds).
• ·Smallest notable positions include Tesla Inc. (1046 shares, $389000 value) and Costco Wholesale Corporation (533 shares, $531000 value).

06-05-2026

BGSF, Inc. filed an 8-K on May 6, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for financial results announcements, but specific revenue, earnings, guidance, or other metrics are NOT_DISCLOSED. No positive or negative performance details, period-over-period comparisons, or forward-looking statements are provided in the filing description.

06-05-2026

Paradigm Capital Management, LLC/NV filed a 13F-HR disclosing 59 equity positions with a total market value of $109,127,000 as of March 31, 2026. The largest holding is J P MORGAN EXCHANGE TRADED F ULTRA SHRT ETF valued at $13,445,000 (265,661 shares), followed by VANGUARD SPECIALIZED FUNDS DIV APP ETF at $12,700,000 (59,053 shares) and VANGUARD WHITEHALL FDS HIGH DIV YLD at $9,244,000 (62,420 shares). No period-over-period changes are available in this filing.

• ·Filing date: May 06, 2026
• ·Report period end: March 31, 2026
• ·Filer address: 6170 Ridgeview Court, Suite F, Reno, NV 89519
• ·All holdings reported as sole investment discretion (SH SOLE)

06-05-2026

HughesLittle Investment Management Ltd. filed its 13F-HR report on May 6, 2026, for the quarter ended March 31, 2026, disclosing 14 equity positions with a total market value of $510815515. Key holdings include Brookfield Corp CL A LTD VT SH (1,541,385 shares valued at $62334365), Uber Technologies Inc (730,133 shares valued at $52518467), and Schwab Charles Corp (703,529 shares valued at $66117655). All positions are held with sole voting authority.

• ·Report filed as of May 6, 2026; period end March 31, 2026
• ·All 14 positions held with sole discretionary voting authority
• ·Firm located at 19 710-688 West Hastings Street, Vancouver, British Columbia, Canada V6B 1P1

06-05-2026

Lumentum Holdings Inc. reported strong Q3 FY2026 results with net revenue of $808.4 million, up 90% YoY from $425.2 million, and net income of $144.2 million versus a $44.1 million loss prior year; nine-month revenue reached $2,007.7 million (+73% YoY from $1,164.3 million) with net income of $226.6 million reversing a $187.4 million loss. Gross profit surged 191% YoY to $357.0 million in Q3, while operating income turned positive at $174.5 million from a $37.7 million loss. However, cost of sales rose 52% YoY to $432.1 million in Q3, R&D expenses increased 19% to $90.6 million, and current portion of long-term debt ballooned to $3,238.6 million from $10.6 million.

• ·Cash provided by operating activities for nine months FY2026: $388.4 million (up from $62.3 million YoY).
• ·Payments for acquisition of property, plant and equipment: $284.5 million for nine months FY2026.
• ·Payment for acquisition of business: $38.0 million.
• ·Total assets as of March 28, 2026: $7,027.9 million (up from $4,218.7 million as of June 28, 2025).
• ·Stockholders’ equity as of March 28, 2026: $2,973.4 million (up from $1,134.7 million as of June 28, 2025).

06-05-2026

AMD reported strong Q1 FY2026 results with net revenue surging 38% YoY to $10,253 million from $7,438 million, gross profit up 45% to $5,416 million, operating income up 83% to $1,476 million, and net income nearly doubling 95% to $1,383 million. Diluted EPS rose to $0.84 from $0.44. However, operating expenses increased 34% YoY to $3,940 million driven by higher R&D (up 39%) and inventories grew 2% QoQ to $8,045 million.

• ·Cash flows from operating activities surged 215% YoY to $2,955 million.
• ·Total current assets increased to $28,628 million from $26,947 million QoQ.
• ·Long-term debt stable at $2,350 million.
• ·Stock repurchases totaled $221 million in Q1 FY2026.

06-05-2026

Atkore Inc. reported net sales growth of 4% YoY to $731M for the three months ended March 27, 2026, and 2% YoY to $1.39B for the six months, but gross profit declined sharply 27% YoY to $136M in the quarter due to higher cost of sales. Operating income improved to $10M from a $52M loss YoY, however a $137M litigation settlement and $26M other expenses drove a wider net loss of $124M in the quarter (vs $50M loss prior) and $109M for six months (vs $4M loss). Cash from operations swung to a $27M use from $161M provided in the prior six-month period.

• ·Total assets stable at $2.85B as of March 27, 2026 vs September 30, 2025.
• ·Inventories decreased to $401M from $485M year-to-date.
• ·Accounts receivable increased to $558M from $447M year-to-date.
• ·Net cash used in operating activities $27M for six months vs provided $161M prior year.
• ·Capital expenditures $26M for six months vs $64M prior year.

06-05-2026

Primoris Services Corp reported Q1 2026 revenue of $1,559.9M, down 5.4% YoY from $1,648.1M, with gross profit declining 21.1% to $134.7M amid higher cost of revenue. Operating income fell sharply 65.3% to $24.4M due to elevated SG&A expenses ($105.8M, up 6.3%) and transaction costs ($4.5M), resulting in net income of $17.4M versus $44.2M YoY. Cash used in operations was $122.6M, compared to $66.2M provided last year, with cash and equivalents dropping to $361.5M from $535.5M QoQ.

• ·Net cash used in operating activities: $122.6M in Q1 2026 vs $66.2M provided in Q1 2025.
• ·Purchase of property and equipment: $27.8M in Q1 2026 vs $40.6M in Q1 2025.
• ·Dividends declared: $0.08 per common share, $4.3M payable.
• ·Basic EPS: $0.32 in Q1 2026 vs $0.82 in Q1 2025.
• ·Total stockholders’ equity increased slightly to $1,684.0M from $1,681.0M QoQ.

06-05-2026

Aventura Private Wealth, LLC filed its 13F-HR on May 6, 2026, disclosing $273,492,748 in holdings across 904 positions as of March 31, 2026, with sole discretionary voting power over all shares. Top holdings include Amazon.com Inc. ($9,105,981, 43,722 shares), Netflix Inc. ($4,715,196, 49,040 shares), and Mastercard Incorporated ($3,775,914, 7,556 shares). The portfolio is highly diversified with no reported changes or performance metrics.

• ·Filing period end date: March 31, 2026
• ·All positions held with sole voting power (SH SOLE); no shared voting or investment discretion reported
• ·Portfolio includes a mix of individual stocks, ETFs, and CEFs across sectors like technology, consumer, healthcare, and REITs

06-05-2026

Flowco Holdings Inc. reported first quarter 2026 revenues of $209.5 million, up 6.2% QoQ from $197.2 million and 8.9% YoY from $192.4 million, with Adjusted EBITDA rising 2.4% QoQ to $85.5 million (14.2% YoY growth) despite a margin contraction to 40.8% from 42.4% QoQ. Production Solutions revenues grew 10.0% QoQ to $140.2 million, but Natural Gas Technologies revenues declined 0.6% QoQ to $69.4 million with EBITDA down 1.1% and margins flat; corporate costs worsened to $(5.6) million. The company closed its acquisition of Valiant Artificial Lift Solutions on March 2, 2026, generated $52.3 million in Free Cash Flow, repurchased $16.5 million in shares, and raised its quarterly dividend 12.5% to $0.09 per share.

• ·Net cash provided by operating activities of $78.7 million in Q1 2026
• ·Total assets increased to $1,897.8 million as of March 31, 2026 from $1,646.4 million as of Dec 31, 2025
• ·Long-term debt net $328.0 million as of March 31, 2026 up from $167.8 million
• ·Quarterly dividend payable May 27, 2026 to shareholders of record May 15, 2026

06-05-2026

Hennessy Capital Investment Corp. VII (HVII) issued a Rule 425 filing disclosing a LinkedIn post by ONE Nuclear Energy LLC on May 5, 2026, regarding their proposed Business Combination. The communication emphasizes extensive forward-looking statements and risks, including potential failure to complete the merger, regulatory approvals, high redemptions, and non-binding commercial relationships with partners like Rolls-Royce, Black & Veatch, and FutureWorx. No financial metrics or timelines for completion are provided, with investors urged to review the Registration Statement and Proxy Statement.

• ·HVII's Annual Report on Form 10-K filed with SEC on March 6, 2026, for year ended December 31, 2025.
• ·Registration Statement on Form S-4 includes preliminary proxy statement/prospectus.
• ·Commercial agreements with Rolls-Royce, Black & Veatch, and FutureWorx are non-binding and subject to definitive execution.

06-05-2026

ITC Holdings Corp. reported Q1 2026 net income of $137M, up 7.9% YoY from $127M, with total operating revenues rising 7.5% to $473M driven by a 9.1% increase in transmission and other services to $433M. However, operating expenses increased 10.1% to $218M and formula rate true-up revenues declined 7.0% to $40M from $43M. Total assets grew 2.5% QoQ to $15,205M as of March 31, 2026 from $14,834M at December 31, 2025, supported by higher property, plant and equipment.

• ·Net cash used in investing activities increased to $400M in Q1 2026 from $349M in Q1 2025 due to higher capex.
• ·Cash and cash equivalents decreased to $3M as of March 31, 2026 from $13M at December 31, 2025.
• ·Commercial paper program size $400M with $381M issued and outstanding at weighted average interest rate of 4.07%.
• ·Dividends to ITC Investment Holdings remained flat at $73M YoY.

06-05-2026

For the three months ended March 31, 2026, CVS Health reported total revenues of $100,426 million, up 6.2% YoY from $94,588 million, with strong growth in products (+7.8% to $62,226 million) and services (+7.1% to $3,835 million), while premiums grew modestly +3.0% to $33,791 million. Net income attributable to CVS Health surged 65.4% YoY to $2,943 million, with diluted EPS rising to $2.30 from $1.41. However, net cash provided by operating activities declined 6.7% to $4,249 million from $4,556 million, operating expenses dipped slightly -0.7% but total operating costs rose 5.0%, and total assets decreased marginally to $252,974 million from $253,538 million at December 31, 2025.

• ·Cash and cash equivalents increased QoQ to $9,542 million from $8,453 million.
• ·Inventories decreased QoQ to $17,770 million from $19,246 million.
• ·Current liabilities declined QoQ to $86,406 million from $88,692 million.
• ·Shareholders' equity attributable to CVS Health rose to $77,456 million from $75,214 million at year-end.

06-05-2026

Apollo Global Management reported first quarter 2026 results ended March 31, 2026, achieving record fee-related earnings and assets under management of $1.03 trillion, marking a significant milestone. The company declared a cash dividend of $0.5625 per share on common stock payable May 29, 2026, and $0.8438 per share on mandatory convertible preferred stock payable July 31, 2026. No declines or flat metrics were disclosed in the release.

• ·Conference call held May 6, 2026 at 8:30 a.m. Eastern Time; replay available on ir.apollo.com.
• ·Common stock dividend record date: May 19, 2026; payment date: May 29, 2026.
• ·Mandatory convertible preferred stock dividend record date: July 15, 2026; payment date: July 31, 2026.
• ·Full Q1 2026 results presentation available on ir.apollo.com.

06-05-2026

For Q1 2026, LeMaitre Vascular Inc reported net sales of $66,551 thousand, up 11.2% YoY from $59,871 thousand, with gross profit rising 16.9% to $48,396 thousand and net income increasing 42.4% to $15,679 thousand. However, total operating expenses grew 6.4% to $30,621 thousand, driven by a 14.9% rise in general and administrative expenses to $12,046 thousand, while R&D expenses remained flat and cash equivalents declined QoQ to $26,851 thousand from $28,244 thousand.

• ·Diluted EPS increased to $0.68 from $0.48 YoY.
• ·Cash dividends declared per common share rose to $0.25 from $0.20.
• ·Net cash provided by operating activities up 67.0% YoY to $15,093 thousand.
• ·Short-term marketable securities increased QoQ to $340,382 thousand from $330,876 thousand.
• ·Stockholders’ equity grew QoQ to $406,622 thousand from $393,516 thousand.

06-05-2026

Walt Disney reported Q2 FY2026 revenues of $25,168 million, up 7% YoY from $23,621 million, with Entertainment revenues rising 10% to $11,715 million and Experiences up 7% to $9,487 million, but Sports operating income declined 5% to $652 million. Total segment operating income increased 4% to $4,603 million, though diluted EPS fell 30% to $1.27 from $1.81; over the six-month period, total segment operating income decreased 3% to $9,203 million and Entertainment operating income dropped 18% to $2,436 million. The company expects FY2026 adjusted EPS growth of 12-16% and at least $8,000 million in share repurchases, while noting healthy domestic parks demand amid macroeconomic uncertainty.

• ·Q3 FY2026 total segment operating income expected at approximately $5,300 million.
• ·FY2027 adjusted EPS expected to grow double-digits, excluding 53rd week impact.
• ·Zootopia franchise surpassed 1 billion hours streamed.
• ·ESPN Men's Tournament Challenge brackets up 7% YoY to 27 million.
• ·Domestic parks attendance expected to improve YoY in Q3.

06-05-2026

Immunocore reported Q1 2026 KIMMTRAK net product sales of $106.7 million, up 14% YoY from $93.9 million, driven by 19.1% US growth to $67.4 million and 4.9% Europe growth to $34.4 million, with net income rising to $13.0 million from $5.0 million. However, R&D expenses increased to $61.1 million from $56.5 million due to Phase 3 trial progression, while SG&A expenses decreased to $37.9 million from $40.2 million. Cash and equivalents stood at $845 million as of March 31, 2026, supporting pipeline advancement including PRISM-MEL-301 and TEBE-AM trials.

• ·KIMMTRAK approved in 39 countries, launched in over 30.
• ·Phase 3 AACR data: 5-year OS 16% vs 8% control (HR 0.67), median OS 21.6 vs 16.9 months.
• ·TEBE-AM Phase 3 enrollment completion expected H1 2026, topline H2 2026.
• ·PRISM-MEL-301 Phase 3 ongoing for first-line advanced cutaneous melanoma.
• ·Potential patient populations: 4,000 for 2L+ CM, 1,200 adjuvant uveal melanoma, 10,000 first-line CM.
• ·CTA filed for IMC-S118AI Dec 2025, Phase 1 H1 2026.
• ·ASCO 2026 posters on May 30 and May 31.

06-05-2026

Exelon reported Q1 2026 GAAP net income of $0.90 per share, flat YoY, and Adjusted operating earnings of $0.91 per share, down slightly from $0.92. While PECO and BGE saw Adjusted earnings increases to $278M (+5%) and $298M (+15%) respectively, ComEd's Adjusted earnings declined to $310M (-5%) and PHI's fell to $180M (-7%). The company affirmed FY2026 Adjusted EPS guidance of $2.81-$2.91 and projected $41.7B in capital expenditures over four years with 7.9% rate base growth.

• ·Completed approximately 43% of planned debt financings through March 31, 2026, including all Holding Company issuances.
• ·All utilities sustained top quartile reliability performance, with ComEd in top decile.
• ·Declared quarterly dividend of $0.42 per share, payable June 15, 2026 to shareholders of record June 4, 2026.
• ·PHI declines primarily due to Pepco Maryland multi-year plan reconciliation and higher depreciation.

06-05-2026

Kyndryl reported fiscal year 2026 revenues of $15.1 billion, flat year-over-year on a reported basis but down 3% on a constant currency basis, with mixed segment performance including United States down 2%, Principal Markets up 4%, Strategic Markets flat at 0%, and Japan down 3%. While GAAP pretax income dipped to $414 million from $435 million and net income fell to $198 million from $252 million, adjusted pretax income increased 21% to $581 million and adjusted EBITDA rose 6% to $2.7 billion. In Q4, revenues declined 1% to $3.8 billion with adjusted EBITDA slightly down to $688 million from $698 million, though the company noted strong hyperscaler-related revenue growth of 59% to $1.9 billion and provided FY2027 outlook for adjusted pretax income of $600-700 million.

• ·Cash flow from operations FY2026: $948 million (vs $942 million FY2025)
• ·Free cash flow FY2026: $406 million (vs $419 million FY2025)
• ·FY2027 outlook: Free cash flow $400-500 million; constant-currency revenue flat to down 2%
• ·Share repurchases since Nov 2024: 14.3 million shares for $398 million (6% of shares outstanding), $302 million capacity remaining
• ·Q4 cash flow from operations: $499 million (vs $581 million prior year)

06-05-2026

Future Vision II Acquisition Corp. received a Nasdaq notice on May 5, 2026, stating non-compliance with the minimum public holders requirement under Listing Rule 5550(a)(3) for continued listing on the Nasdaq Capital Market. The notice provides 45 days until June 22, 2026, to submit a compliance plan, with a possible 180-day extension if accepted, but offers no assurance of regaining or maintaining compliance. The Company is evaluating options but faces delisting risk with no immediate impact on trading.

• ·Nasdaq Listing Rule 5550(a)(3) is the specific rule violated.
• ·Principal executive offices: Xiandai Tongxin Building 201 Xin Jinqiao Road, Rm 302, Pudong New District, Shanghai, China.
• ·Registrant telephone: + (86) 136 0300 0540.
• ·Emerging growth company: Yes.

06-05-2026

Advantage Solutions Inc. reported Q1 2026 revenues of $869.6 million, up 5.8% YoY from $821.8 million, and Adjusted EBITDA of $67.7 million, up 16.4% YoY, driven by Experiential Services revenue growth of 22.8% and Retailer Services profitability improvement. However, Branded Services revenues declined 11.3% YoY with Adjusted EBITDA down 25.3%, and net loss widened 28.0% to $71.8 million from $56.1 million. The company strengthened its balance sheet with $131 million debt paydown, ending with $144 million cash, and reaffirmed 2026 guidance for flat to low single-digit revenue growth and flat to down mid single-digit Adjusted EBITDA.

• ·Net Leverage Ratio of 4.2x as of March 31, 2026
• ·Capex of $11 million in Q1 2026
• ·Adjusted EBITDA Margin improved to 7.8% from 7.1% YoY
• ·2026 Guidance: Adjusted Unlevered Free Cash Flow $250-$275M; Net Interest Expense $160-$170M; Capex $50-$60M
• ·Debt maturities extended to 2030

06-05-2026

Global Payments reported first quarter 2026 GAAP revenue of $2.97 billion (up 63.1% YoY) and adjusted net revenue of $2.86 billion (up 29.5% YoY), with adjusted EPS of $2.96 (up 10% YoY); however, GAAP diluted EPS was ($6.59), down from $1.24 YoY, primarily due to discontinued operations losses and higher interest expense (up 63.2%). On a normalized basis, adjusted net revenue grew 5.5% (4.5% constant currency), and adjusted operating margin expanded 110 basis points to 39.9%. The company announced a $500 million accelerated share repurchase plan as part of over $2 billion expected returns to shareholders in 2026 and reaffirmed full-year normalized adjusted net revenue growth of approximately 5% and adjusted EPS of $13.80 to $14.00.

• ·Board of Directors approved dividend of $0.25 per share, payable June 26, 2026 to shareholders of record June 12, 2026.
• ·Expects to return over $2 billion to shareholders through repurchases and dividends in 2026.
• ·Issuer Solutions accounted as discontinued operations effective Q2 2025.

06-05-2026

Anavex Life Sciences Corp. appointed Terrie Kellmeyer, PhD, former Senior Vice President of Clinical Development, as Interim Chief Executive Officer following the departure of President and CEO Christopher Missling, PhD, on April 30, 2026. Dr. Kellmeyer will advance the company's pipeline, including lead candidate oral blarcamesine for early Alzheimer’s disease, leveraging her extensive experience in regulatory submissions and clinical development. The company highlighted a strong cash balance with no long-term debt but disclosed a delay in filing its Form 10-Q for the quarter ended March 31, 2026, via a Form 12b-25 extension.

• ·CEO departure and board resignation requested on April 30, 2026
• ·Form 10-Q extension via Form 12b-25 for quarter ended March 31, 2026
• ·Planned conference call and webcast for second quarter 2026 financial results